AMG FOURIER - Evaluation of an investigational medication with statin therapy for patients with cardiovascular disease
A double-blind, placebo controlled, multi center study to see if AMG 145 with statin therapy can help reduce the amount of LDL-cholesterol in the blood stream which might lower the risk of major cardiovascular events.
Studies have shown that abnormal amounts of lipids in the blood is among the leading risk factors for cardiovascular deaths. The purpose of this study is to find out more about the investigational product called AMG 145, a human antibody that binds to a protein that is produced by the liver. By binding to this protein, AMG 145 allows LDL-cholesterol (bad cholesterol) to move more efficiently out of the bloodstream. Less of this lipid in the bloodstream helps with cleaner blood vessels which means blood can flow more freely. This can decrease the chances of tissue damage caused by blocked blood vessels of the heart or brain.
To participate in this trial, patients need to be between the ages of 40 and 85 and diagnosed with myocardial infarction or stroke within the last 5 years. For more information, visit the Cardiovascular Research site.